Wlds-mediated protection of dopaminergic fibers in an animal model of Parkinson disease.
D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D002470:Cell Survival / Q000502:physiology; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D007150:Immunohistochemistry; D051379:Mice; D008817:Mice, Mutant Strains; D009043:Motor Activity / Q000187:drug effects; D009419:Nerve Tissue Proteins / Q000378:metabolism*; D016627:Oxidopamine / Q000378:metabolism; D010300:Parkinson Disease / Q000378:metabolism*; D017729:Presynaptic Terminals / Q000378:metabolism / Q000502:physiology*; D013378:Substantia Nigra / Q000503:physiopathology; D014855:Wallerian Degeneration / Q000378:metabolism* / Q000503:physiopathology
D009419:Nerve Tissue Proteins; C442580:Wld protein, mouse; D016627:Oxidopamine; D000661:Amphetamine; D004298:Dopamine